Project: Biomarker based diagnosis of rapid progressive dementias - optimisation of diagnostic protocols

DEMTEST has established a large European and global collaboration between national surveillance units and dementia research centres, facilitating cooperation between neurologists, neuropathologists and neuroscientists. Our goals are:  to harmonize the protocols involved in patient documentation, biomaterial sampling/ storage, biomarker testing/assay analysis and data sharing  to standardise a more precise diagnosis in patients with rapidly progressive dementia by analysis of the biochemical markers in the cerebrospinal fluid and blood.  to improve CSF based diagnosis in dementia by application of new methodologies We work on standardisation of tests that are currently available and harmonise their use between centers worldwide. We define standards for biochemically based diagnosis in most relevant rapid progressive dementia such as CJD and rapidly progressive Alzheimer’s disease. We will improve innovative methods for amplification assays for mis-folded proteins and introduce their use into clinical routine. As an add-on value, we will define criteria for early differential diagnosis between rapidly progressive neurodegenerative or potentially reversible dementia.

Acronym DEMTEST (Reference Number: JPND-304-008)
Duration 01/05/2012 - 30/04/2015
Project Topic Neurodegenerative disease
Website visit project website
Network JPND
Call Pilot JPND Joint Transnational Call for optimisation of biomarkers and harmonisation of their use

Project partner

Number Name Role Country
1 Georg-August University Göttingen Coordinator Germany
2 Hopital Lariboisiere AP-HP Partner France
3 UMR-INRA-EVNT Partner France
4 Heinrich Heine University Medical School, Düsseldorf Partner Germany
5 Ludwig-Maximilians-University Munich Partner Germany
6 Aristotle University of Thessaloniki Partner Greece
7 IRCCS Neuromed - Istituto Mediterraneo di Neuroscienze, University “Sapienza”, Rome Partner Italy
8 Medical University of Lodz Partner Poland
9 University of Coimbra Partner Portugal
10 Slovak Medical University Bratislava Partner Slovakia
11 University Psychiatric Hospital, Ljubljana Partner Slovenia
12 Carlos III National Health Institute Partner Spain
13 IFIMAV and CIBERNED, University Hospital Partner Spain
14 Swedish Institute of Communicable Disease Control Partner Sweden
15 University Hospital Zürich Partner Switzerland
16 UCL Institute of Neurology Partner United Kingdom
17 Western General Hospital Partner United Kingdom